高热腹腔化疗顺铂后急性肾损伤。
Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
机构信息
Hepatobilliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia;
St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW, Australia.
出版信息
Anticancer Res. 2021 Mar;41(3):1641-1646. doi: 10.21873/anticanres.14926.
BACKGROUND/AIM: Cisplatin increases the risk of acute kidney injury (AKI) during systemic chemotherapy. However, little is known about its risk of inducing AKI when used during intraperitoneal chemotherapy. This study aimed to determine the incidence of AKI in patients undergoing cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) with cisplatin.
PATIENTS AND METHODS
A retrospective analysis of patients who received cisplatin-based HIPEC from November 2008 to March 2018 was undertaken to determine the incidence of AKI.
RESULTS
A total of 111 patients were identified. The incidence of AKI was 15.3% (17/111). Univariate analysis showed increased peritoneal cancer index (PCI), low intraoperative and post-operative urine output were significantly associated with the development of AKI. Multivariate analyses did not identify any significant predictors factors for AKI.
CONCLUSION
Cisplatin-based HIPEC is associated with AKI. At our centre, the incidence of AKI was 15.3%. Risk factors that may influence its development include high PCI and low perioperative diuresis.
背景/目的：顺铂在全身化疗期间会增加急性肾损伤（AKI）的风险。然而，对于顺铂用于腹腔内化疗时是否会导致 AKI 的风险知之甚少。本研究旨在确定接受细胞减灭术（CRS）和顺铂加热腹腔内化疗（HIPEC）的患者发生 AKI 的发生率。
方法
对 2008 年 11 月至 2018 年 3 月期间接受顺铂 HIPEC 的患者进行回顾性分析，以确定 AKI 的发生率。
结果
共确定了 111 例患者。AKI 的发生率为 15.3%（17/111）。单因素分析表明，腹膜癌指数（PCI）升高、术中及术后尿量减少与 AKI 的发生显著相关。多因素分析未发现 AKI 的任何显著预测因素。
结论
顺铂 HIPEC 与 AKI 相关。在我们中心，AKI 的发生率为 15.3%。可能影响其发展的危险因素包括高 PCI 和围手术期尿量减少。
Zotero 插件